Celularity Net Worth
Celularity Net Worth Breakdown | CELUW |
Celularity Net Worth Analysis
Celularity's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Celularity's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Celularity's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Celularity's net worth analysis. One common approach is to calculate Celularity's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Celularity's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Celularity's net worth. This approach calculates the present value of Celularity's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Celularity's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Celularity's net worth. This involves comparing Celularity's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Celularity's net worth relative to its peers.
Enterprise Value |
|
To determine if Celularity is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Celularity's net worth research are outlined below:
| Celularity is way too risky over 90 days horizon | |
| Celularity has some characteristics of a very speculative penny stock | |
| Celularity appears to be risky and price may revert if volatility continues | |
| Celularity has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.77 M. Net Loss for the year was (196.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Celularity has accumulated about 38 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Celularitys Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell ... |
Celularity Quarterly Good Will |
|
Project Celularity's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.49) | |
| Return On Capital Employed | (2.51) | (2.39) | |
| Return On Assets | (1.36) | (1.30) | |
| Return On Equity | (4.79) | (4.55) |
When accessing Celularity's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Celularity's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Celularity's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Celularity's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Celularity. Check Celularity's Beneish M Score to see the likelihood of Celularity's management manipulating its earnings.
Evaluate Celularity's management efficiency
The company has return on total asset (ROA) of (0.1463) % which means that it has lost $0.1463 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5423) %, meaning that it generated substantial loss on money invested by shareholders. Celularity's management efficiency ratios could be used to measure how well Celularity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.49 in 2024. Return On Capital Employed is likely to climb to -2.39 in 2024. At this time, Celularity's Non Currrent Assets Other are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.30 | 2.18 | |
| Tangible Book Value Per Share | 1.27 | 1.33 | |
| Enterprise Value Over EBITDA | (0.59) | (0.62) | |
| Price Book Value Ratio | 1.07 | 1.13 | |
| Enterprise Value Multiple | (0.59) | (0.62) | |
| Price Fair Value | 1.07 | 1.13 | |
| Enterprise Value | 109.2 M | 103.7 M |
Celularity benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Revenue 42.7 M | Quarterly Revenue Growth 3.122 | Revenue Per Share 2.099 | Return On Equity (1.54) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celularity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celularity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celularity insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pecora Andrew L over two months ago Disposition of 153718 shares by Pecora Andrew L of Celularity at 10.21 subject to Rule 16b-3 | ||
Hariri Robert J over three months ago Disposition of 2084854 shares by Hariri Robert J of Celularity at 3.0 subject to Rule 16b-3 | ||
Fletcher Kyle over three months ago Disposition of 201 shares by Fletcher Kyle of Celularity at 0.7141 subject to Rule 16b-3 | ||
Brigido Stephen over three months ago Acquisition by Brigido Stephen of 153718 shares of Celularity at 10.23 subject to Rule 16b-3 | ||
Von Eschenbach Andrew C. over three months ago Acquisition by Von Eschenbach Andrew C. of 277778 shares of Celularity at 0.7503 subject to Rule 16b-3 | ||
Hariri Robert J over three months ago Acquisition by Hariri Robert J of 2084854 shares of Celularity at 0.8343 subject to Rule 16b-3 | ||
Beers David C over six months ago Acquisition by Beers David C of 250000 shares of Celularity subject to Rule 16b-3 |
Celularity Earnings per Share Projection vs Actual
Celularity Corporate Management
| Carlos Ramirez | SVP Relations | Profile | |
| Sharmila MD | Senior Safety | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Tim Wilk | Senior Operations | Profile | |
| Ramji Krishnan | Chief Officer | Profile | |
| Bradley Glover | Ex COO | Profile | |
| CPA MS | Treasurer | Profile |
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.